Physician profile
Inderjeet Kaur
NPI 1861815607
$297.37
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $51.07 · 2021: $104 · 2022: $99.51 · 2023: $42.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $42.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $42.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $102.22 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $67.36 | 2021 | |
| Biogen, INC. | $42.50 | 2023 | |
| Alkermes, INC. | $41.71 | 2022 | |
| Abbvie INC. | $17.38 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $13.12 | 2022 | |
| Neurocrine Biosciences, INC. | $13.08 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Inderjeet Kaur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.